BioCentury
ARTICLE | Clinical News

Viagra sildenafil regulatory update

August 2, 2010 7:00 AM UTC

An FDA panel voted 7-6 on Thursday that pulmonary vascular resistance index (PVRI) could be used to demonstrate effectiveness and derive dosing information in pediatric trials of pulmonary arterial hypertension (PAH) drugs that already are approved in adults. The Cardiovascular and Renal Drugs Advisory Committee did not vote on the separate question of whether Pfizer could use available hemodynamics data in children to support pediatric approval of PAH drug Revatio sildenafil. An FDA spokesperson said the panel did not have enough information to vote on the topic. ...